These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32495405)

  • 61. Regulation of advanced therapy medicinal products in Europe and the role of academia.
    Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
    Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cell and Gene Therapies: European View on Challenges in Translation and How to Address Them.
    Rousseau CF; Mačiulaitis R; Śladowski D; Narayanan G
    Front Med (Lausanne); 2018; 5():158. PubMed ID: 29911104
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity.
    Callenbach MHE; Goettsch WG; Mantel-Teeuwisse AK; Trusheim M
    Drug Discov Today; 2024 Jul; 29(7):104048. PubMed ID: 38830504
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe.
    Avşar TS; Elvidge J; Hawksworth C; Kenny J; Németh B; Callenbach M; Ringkvist J; Dawoud D
    Value Health; 2024 Nov; 27(11):1497-1506. PubMed ID: 39094693
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Advanced Therapy Medicinal Products for the Eye: Definitions and Regulatory Framework.
    López-Paniagua M; de la Mata A; Galindo S; Blázquez F; Calonge M; Nieto-Miguel T
    Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33800934
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Regulation of advanced therapies in Europe: Are we on the right track?
    Izeta A; Cuende N
    Cell Stem Cell; 2023 Aug; 30(8):1013-1016. PubMed ID: 37541207
    [TBL] [Abstract][Full Text] [Related]  

  • 68. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Safety monitoring of cell-based medicinal products (CBMPs)].
    Funk MB; Frech M; Spranger R; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1239-46. PubMed ID: 26391098
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Creating conditions for the success of the French industrial advanced therapy sector.
    Lirsac PN; Blin O; Magalon J; ; Angot P; de Barbeyrac E; Bilbault P; Bourg E; Damour O; Faure P; Ferry N; Garbil B; Larghero J; Nguon M; Pattou F; Thumelin S; Yates F
    Therapie; 2015; 70(1):69-94. PubMed ID: 25747840
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Encountering Challenges with the EU Regulation on Advance Therapy Medical Products.
    Mansnérus J
    Eur J Health Law; 2015 Dec; 22(5):426-61. PubMed ID: 26665690
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evaluation of institutional readiness at sites within the UK NHS using a novel advanced therapy medicinal product assessment tool.
    Wotherspoon L; Buchan R; Morrison E; Amatt G
    Regen Med; 2021 Mar; 16(3):253-268. PubMed ID: 33724873
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Advanced Therapy Medicinal Products: How to Bring Cell-Based Medicinal Products Successfully to the Market - Report from the CAT-DGTI-GSCN Workshop at the DGTI Annual Meeting 2014.
    Celis P; Ferry N; Hystad M; Schüßler-Lenz M; Doevendans PA; Flory E; Beuneu C; Reischl I; Salmikangas P
    Transfus Med Hemother; 2015 May; 42(3):194-9. PubMed ID: 26195933
    [TBL] [Abstract][Full Text] [Related]  

  • 74. 2023, A Landmark Year in Biomedical Research; A Turning Point in Medical History.
    Sadri B; Vosough M
    Cell J; 2024 Mar; 26(3):210-211. PubMed ID: 38628094
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation.
    de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P
    Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products].
    Reiss M; Büttel IC; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Horses for courses: an approach to the qualification of clinical trial sites and investigators in ATMPs.
    Hildebrandt M
    Drug Discov Today; 2020 Feb; 25(2):265-268. PubMed ID: 31628993
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Health technology assessment in England and Wales.
    Stevens A; Milne R
    Int J Technol Assess Health Care; 2004; 20(1):11-24. PubMed ID: 15176173
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.